Download - Bayer HealthCare

Bayer HealthCare manufactures products at almost 60 sites around the world which
are managed by Product Supply. The production of active ingredients for prescription
medicines is conducted primarily at the production sites in Wuppertal and Bergkamen
(Germany) and Berkeley and Emeryville (united States). They are processed and packaged
as finished pharmaceuticals in plants around the world.
A broad spectrum of different pharmaceutical presentations is covered: solid formulations such
as tablets, sugar-coated tablets and powders, semi-solid ointments and creams, and
liquid drug products for application, for example, as injections or infusions. Hormonal
contraceptives are produced as sugar- or film-coated tablets but also, for example, as
intrauterine systems. These formulation and packaging activities are based in Berlin,
Leverkusen and Weimar (Germany), Garbagnate (Italy), Turku (Finland), São Paulo
(Brazil), Beijing (China), as well as various other sites in Europe, Asia and Latin America.
Kogenate, a drug product for the treatment of hemophilia, is manufactured in Berkeley
(United States) using a biotechnology process, while Betaferon/Betaseron for the
treatment of multiple sclerosis is produced in Emeryville (United States).
The main production sites for non-prescription (over-the-counter) drug products are
located in Bitterfeld-Wolfen and Grenzach-Wyhlen (Germany), Cimanggis (Indonesia),
Lerma (Mexico), Myerstown (United States) and Madrid (Spain). The globally marketed
animal health products are mainly manufactured at the sites in Kiel (Germany) and
Shawnee (United States).
In addition to drug products for humans and animals, medical devices for diagnosis
and therapy are produced in the United States. Bayer HealthCare supplies a total of
more than 20,000 articles. The reason for this large number is the different presentations
of individual products and packaging – for example, different formulations,
dosages, pack sizes and language versions.
Bayer HealthCare Product Supply steers the subgroup’s entire supply chain, from raw
material sourcing through manufacturing to distribution, utilizing a global production
network consisting of its own sites and those of contract manufacturers. In this way
the company aims for continuous improvement of costs, flexibility and delivery reliability,
maintaining high standards of quality, health, safety and environmental protection on
a global basis.
The manufacture of pharmaceutical products is subject to extraordinarily stringent
quality standards. These standards are known collectively as “Good Manufacturing
Practice” (GMP). Compliance with these requirements is regularly audited by internal
experts, regulatory authorities and external consultants.
ProDuCT SuPPly
21